| Literature DB >> 29544348 |
Paolo Calabrò1, Felice Gragnano1, Marco Di Maio1, Giuseppe Patti2, Emilia Antonucci3, Plinio Cirillo4, Paolo Gresele5, Gualtiero Palareti3, Vittorio Pengo6, Pasquale Pignatelli7, Mauro Pennacchi8, Antonino Granatelli8, Stefano De Servi9, Leonardo De Luca8, Rossella Marcucci10.
Abstract
The epidemiology and management of patients with acute coronary syndromes (ACSs) have evolved. We aimed to describe recent demographics and therapeutic changes in the Italian ACS population. We analyzed data from 2 multicenter consecutive Italian registries (the EYESHOT [EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalised in iTalian cardiac care units] and START-ANTIPLATELET registries) enrolling patients with ACS between December 2013 and June 2016. An overall population of 3756 patients with ACS was enrolled: 2585 in the EYESHOT and 1171 in the START-ANTIPLATELET. Compared with the EYESHOT, patients in the START-ANTIPLATELET registry presented more frequently with ST-segment elevation myocardial infarction and were more often smokers and dyslipidemic (all P < .001) and had atrial fibrillation ( P = .018) but were less frequently aged ≥75 years and with a history of major bleeding (all P < .001). Analysis of treatment strategy showed a significant increase in the use of percutaneous coronary intervention, drug-eluting stents, dual antiplatelet therapy, and ticagrelor in the START-ANTIPLATELET (all P < .001), with a substantial decline in the proportion of patients conservatively managed and on clopidogrel at discharge ( P < .001). A lower rate of in-hospital events was recorded in the START-ANTIPLATELET compared with the EYESHOT. The START-ANTIPLATELET and EYESHOT registries provide consecutive snapshots in the contemporary management of patients with ACS in Italy, showing important changes in both demographic characteristics and treatment strategies.Entities:
Keywords: EYESHOT study; START-ANTIPLATELET registry; acute coronary syndromes; antithrombotic therapy; percutaneous coronary intervention
Mesh:
Substances:
Year: 2018 PMID: 29544348 DOI: 10.1177/0003319718760917
Source DB: PubMed Journal: Angiology ISSN: 0003-3197 Impact factor: 3.619